P53 in the cns: Perspectives on development, stem cells, and cancer

Genes and Cancer

Volumn 2, Issue 4, 2011, Pages 431-442

  Mendrysa, Susan M ^a   Ghassemifar, Sara ^a   Malek, Reem ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

apoptosis; birth defects; cancer stem cell; glioblastoma; MDM2; MDM4; medulloblastoma; nervous system; neural stem cell; p53

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

APOPTOSIS; ARTICLE; BRAIN NERVE CELL; BRAIN REGION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FATE; CELL GROWTH; CELL RENEWAL; CELL STRESS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; EMBRYO DEATH; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; MEDULLOBLASTOMA; NEOPLASM; NERVE CELL DEGENERATION; NERVE CELL GROWTH; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEURAL TUBE DEFECT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REGULATORY MECHANISM; SENESCENCE; STEM CELL; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

EID: 80053008491     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911409736     Document Type: Article

References (164)

1. Oren M.Regulation of the p53 tumor suppressor protein.J Biol Chem. 1999;274:36031-4.
2. Oren M.Decision making by p53: life, death and cancer.Cell Death Differ. 2003;10:431-42.
3. Lane DP.Cancer. p53, guardian of the genome.Nature. 1992;358:15-6.
4. Morrison RS,Kinoshita Y,Johnson MD,Guo W,Garden GA.p53-dependent cell death signaling in neurons.Neurochem Res. 2003;28:15-27.
5. Culmsee C,Mattson MP.p53 in neuronal apoptosis.Biochem Biophys Res Commun. 2005;331:761-77.
6. Schmid P,Lorenz A,Hameister H,Montenarh M.Expression of p53 during mouse embryogenesis.Development. 1991;113:857-65.
7. Rogel A,Popliker M,Webb CG,Oren M.p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors.Mol Cell Biol. 1985;5:2851-5.
8. Gottlieb E,Haffner R,King A, et al.Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.EMBO J. 1997;16:1381-90.
9. Komarova EA,Chernov MV,Franks R, et al.Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.EMBO J. 1997;16:1391-400.
10. MacCallum DE,Hupp TR,Midgley CA, et al.The p53 response to ionising radiation in adult and developing murine tissues.Oncogene. 1996;13:2575-87.
11. Armstrong JF,Kaufman MH,Harrison DJ,Clarke AR.High-frequency developmental abnormalities in p53-deficient mice.Curr Biol. 1995;5:931-6.
12. Sah VP,Attardi LD,Mulligan GJ,Williams BO,Bronson RT,Jacks T.A subset of p53-deficient embryos exhibit exencephaly.Nat Genet. 1995;10:175-80.
13. Hosako H,Francisco LE,Martin GS,Mirkes PE.The roles of p53 and p21 in normal development and hyperthermia-induced malformations.Birth Defects Res B Dev Reprod Toxicol. 2009;86:40-7.
14. Ikeda S,Hawes NL,Chang B,Avery CS,Smith RS,Nishina PM.Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice.Invest Ophthalmol Vis Sci. 1999;40:1874-8.
15. Gao Y,Sun Y,Frank KM, et al.A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis.Cell. 1998;95:891-902.
16. Frank KM,Sharpless NE,Gao Y, et al.DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway.Mol Cell. 2000;5:993-1002.
17. Sugo N,Aratani Y,Nagashima Y,Kubota Y,Koyama H.Neonatal lethality with abnormal neurogenesis in mice deficient in DNA polymerase beta.EMBO J. 2000;19:1397-404.
18. Clarke AR,Maandag ER,van Roon M, et al.Requirement for a functional Rb-1 gene in murine development.Nature. 1992;359:328-30.
19. Lee EY,Chang CY,Hu N, et al.Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis.Nature. 1992;359:288-94.
20. Jacks T,Fazeli A,Schmitt EM,Bronson RT,Goodell MA,Weinberg RA.Effects of an Rb mutation in the mouse.Nature. 1992;359:295-300.
21. Tsai KY,Hu Y,Macleod KF,Crowley D,Yamasaki L,Jacks T.Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos.Mol Cell. 1998;2:293-304.
22. Ziebold U,Reza T,Caron A,Lees JA.E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos.Genes Dev. 2001;15:386-91.
23. Tsai KY,MacPherson D,Rubinson DA,Crowley D,Jacks T.ARF is not required for apoptosis in Rb mutant mouse embryos.Curr Biol. 2002;12:159-63.
24. MacPherson D,Sage J,Crowley D,Trumpp A,Bronson RT,Jacks T.Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system.Mol Cell Biol. 2003;23:1044-53.
25. Momand J,Zambetti GP,Olson DC,George D,Levine AJ.The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.Cell. 1992;69:1237-45.
26. Oliner JD,Pietenpol JA,Thiagalingam S,Gyuris J,Kinzler KW,Vogelstein B.Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.Nature. 1993;362:857-60.
27. Haupt Y,Maya R,Kazaz A,Oren M.Mdm2 promotes the rapid degradation of p53.Nature. 1997;387:296-9.
28. Honda R,Tanaka H,Yasuda H.Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.FEBS Lett. 1997;420:25-7.
29. Kubbutat MH,Jones SN,Vousden KH.Regulation of p53 stability by Mdm2.Nature. 1997;387:299-303.
30. Shvarts A,Steegenga WT,Riteco N, et al.MDMX: a novel p53-binding protein with some functional properties of MDM2.EMBO J. 1996;15:5349-57.
31. Jackson MW,Berberich SJ.MdmX protects p53 from Mdm2-mediated degradation.Mol Cell Biol. 2000;20:1001-7.
32. Jones SN,Roe AE,Donehower LA,Bradley A.Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.Nature. 1995;378:206-8.
33. Montes de Oca Luna R,Wagner DS,Lozano G.Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.Nature. 1995;378:203-6.
34. Parant J,Chavez-Reyes A,Little NA, et al.Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.Nat Genet. 2001;29:92-5.
35. Migliorini D,Lazzerini Denchi E,Danovi D, et al.Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.Mol Cell Biol. 2002;22:5527-38.
36. Daujat S,Neel H,Piette J.Preferential expression of Mdm2 oncogene during the development of neural crest and its derivatives in mouse early embryogenesis.Mech Dev. 2001;103:163-5.
37. Francoz S,Froment P,Bogaerts S, et al.Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.Proc Natl Acad Sci U S A. 2006;103:3232-7.
38. Xiong S,Van Pelt CS,Elizondo-Fraire AC,Liu G,Lozano G.Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.Proc Natl Acad Sci U S A. 2006;103:3226-31.
39. Malek R,Matta J,Taylor N,Perry ME,Mendrysa SM.The p53 inhibitor MDM2 facilitates sonic hedgehog-mediated tumorigenesis and influences cerebellar foliation.PLoS ONE. 2011;6:e17884.
40. Mendrysa SM,McElwee MK,Michalowski J,O'Leary KA,Young KM,Perry ME.mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation.Mol Cell Biol. 2003;23:462-72.
41. Ringshausen I,O'Shea CC,Finch AJ,Swigart LB,Evan GI.Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.Cancer Cell. 2006;10:501-14.
42. Toledo F,Wahl GM.Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.Nat Rev. 2006;6:909-23.
43. Sohur US,Emsley JG,Mitchell BD,Macklis JD.Adult neurogenesis and cellular brain repair with neural progenitors, precursors and stem cells.Philos Trans R Soc Lond B Biol Sci. 2006;361:1477-97.
44. Temple S.The development of neural stem cells.Nature. 2001;414:112-7.
45. Reynolds BA,Weiss S.Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system.Science. 1992;255:1707-10.
46. Richards LJ,Kilpatrick TJ,Bartlett PF.De novo generation of neuronal cells from the adult mouse brain.Proc Natl Acad Sci U S A. 1992;89:8591-5.
47. Kempermann G,Kuhn HG,Gage FH.Experience-induced neurogenesis in the senescent dentate gyrus.J Neurosci. 1998;18:3206-12.
48. Lee A,Kessler JD,Read TA, et al.Isolation of neural stem cells from the postnatal cerebellum.Nat Neurosci. 2005;8:723-9.
49. Reya T,Clevers H.Wnt signalling in stem cells and cancer.Nature. 2005;434:843-50.
50. Tropepe V,Coles BL,Chiasson BJ, et al.Retinal stem cells in the adult mammalian eye.Science. 2000;287:2032-6.
51. Nagao M,Campbell K,Burns K,Kuan CY,Trumpp A,Nakafuku M.Coordinated control of self-renewal and differentiation of neural stem cells by Myc and the p19ARF-p53 pathway.J Cell Biol. 2008;183:1243-57.
52. Meletis K,Wirta V,Hede SM,Nister M,Lundeberg J,Frisen J.p53 suppresses the self-renewal of adult neural stem cells.Development. 2006;133:363-9.
53. van Lookeren Campagne M,Gill R.Tumor-suppressor p53 is expressed in proliferating and newly formed neurons of the embryonic and postnatal rat brain: comparison with expression of the cell cycle regulators p21Waf1/Cip1, p27Kip1, p57Kip2, p16Ink4a, cyclin G1, and the proto-oncogene Bax.J Comp Neurol. 1998;397:181-98.
54. Gil-Perotin S,Marin-Husstege M,Li J, et al.Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors.J Neurosci. 2006;26:1107-16.
55. Armesilla-Diaz A,Bragado P,Del Valle I, et al.p53 regulates the self-renewal and differentiation of neural precursors.Neuroscience. 2009;158:1378-89.
56. Stecca B,Ruiz i Altaba A.A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers.EMBO J. 2009;28:663-76.
57. Doetsch F,Caille I,Lim DA,Garcia-Verdugo JM,Alvarez-Buylla A.Subventricular zone astrocytes are neural stem cells in the adult mammalian brain.Cell. 1999;97:703-16.
58. Doetsch F,Garcia-Verdugo JM,Alvarez-Buylla A.Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain.J Neurosci. 1997;17:5046-61.
59. Alvarez-Buylla A,Kohwi M,Nguyen TM,Merkle FT.The heterogeneity of adult neural stem cells and the emerging complexity of their niche.Cold Spring Harb Symp Quant Biol. 2008;73:357-65.
60. Bonnet D,Dick JE.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.Nat Med. 1997;3:730-7.
61. Al-Hajj M,Wicha MS,Benito-Hernandez A,Morrison SJ,Clarke MF.Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci U S A. 2003;100:3983-8.
62. Li C,Heidt DG,Dalerba P, et al.Identification of pancreatic cancer stem cells.Cancer Res. 2007;67:1030-7.
63. O'Brien CA,Pollett A,Gallinger S,Dick JE.A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.Nature. 2007;445:106-10.
64. Singh SK,Hawkins C,Clarke ID, et al.Identification of human brain tumour initiating cells.Nature. 2004;432:396-401.
65. Hemmati HD,Nakano I,Lazareff JA, et al.Cancerous stem cells can arise from pediatric brain tumors.Proc Natl Acad Sci U S A. 2003;100:15178-83.
66. Fomchenko EI,Holland EC.Stem cells and brain cancer.Exp Cell Res. 2005;306:323-9.
67. Reya T,Morrison SJ,Clarke MF,Weissman IL.Stem cells, cancer, and cancer stem cells.Nature. 2001;414:105-11.
68. Muller PA,Vousden KH,Norman JC.p53 and its mutants in tumor cell migration and invasion.J Cell Biol. 2011;192:209-18.
69. Burness ML,Sipkins DA.The stem cell niche in health and malignancy.Semin Cancer Biol. 2010;20:107-15.
70. Serrano M,Lin AW,McCurrach ME,Beach D,Lowe SW.Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.Cell. 1997;88:593-602.
71. Graeber TG,Osmanian C,Jacks T, et al.Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.Nature. 1996;379:88-91.
72. Maltzman W,Czyzyk L.UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.Mol Cell Biol. 1984;4:1689-94.
73. Kastan MB,Zhan Q,el-Deiry WS, et al.A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.Cell. 1992;71:587-97.
74. Yonish-Rouach E,Resnitzky D,Lotem J,Sachs L,Kimchi A,Oren M.Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.Nature. 1991;352:345-7.
75. Hollstein M,Sidransky D,Vogelstein B,Harris CC.p53 mutations in human cancers.Science. 1991;253:49-53.
76. Moll UM,Riou G,Levine AJ.Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.Proc Natl Acad Sci U S A. 1992;89:7262-6.
77. Crook T,Tidy JA,Vousden KH.Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.Cell. 1991;67:547-56.
78. Scheffner M,Munger K,Byrne JC,Howley PM.The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.Proc Natl Acad Sci U S A. 1991;88:5523-7.
79. Florenes VA,Maelandsmo GM,Forus A,Andreassen A,Myklebost O,Fodstad O.MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.J Natl Cancer Inst. 1994;86:1297-302.
80. Oliner JD,Kinzler KW,Meltzer PS,George DL,Vogelstein B.Amplification of a gene encoding a p53-associated protein in human sarcomas.Nature. 1992;358:80-3.
81. Polkinghorn WR,Tarbell NJ.Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification.Nat Clin Pract Oncol. 2007;4:295-304.
82. Kleihues P,Schauble B,zur Hausen A,Esteve J,Ohgaki H.Tumors associated with p53 germline mutations: a synopsis of 91 families.Am J Pathol. 1997;150:1-13.
83. Barel D,Avigad S,Mor C,Fogel M,Cohen IJ,Zaizov R.A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family.Cancer Genet Cytogenet. 1998;103:1-6.
84. Marino S,Vooijs M,van Der Gulden H,Jonkers J,Berns A.Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum.Genes Dev. 2000;14:994-1004.
85. Shakhova O,Leung C,van Montfort E,Berns A,Marino S.Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2.Cancer Res. 2006;66:5190-200.
86. Tong WM,Ohgaki H,Huang H,Granier C,Kleihues P,Wang ZQ.Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice.Am J Pathol. 2003;162:343-52.
87. Wetmore C,Eberhart DE,Curran T.Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched.Cancer Res. 2001;61:513-6.
88. Adesina AM,Nalbantoglu J,Cavenee WK.p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma.Cancer Res. 1994;54:5649-51.
89. Ferretti E,De Smaele E,Di Marcotullio L,Screpanti I,Gulino A.Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm.Trends Mol Med. 2005;11:537-45.
90. Saylors RL,Sidransky D,Friedman HS, et al.Infrequent p53 gene mutations in medulloblastomas.Cancer Res. 1991;51:4721-3.
91. Momand J,Jung D,Wilczynski S,Niland J.The MDM2 gene amplification database.Nucleic Acids Res. 1998;26:3453-9.
92. Raffel C,Thomas GA,Tishler DM,Lassoff S,Allen JC.Absence of p53 mutations in childhood central nervous system primitive neuroectodermal tumors.Neurosurgery. 1993;33:301-5.
93. Badiali M,Iolascon A,Loda M, et al.p53 gene mutations in medulloblastoma: immunohistochemistry, gel shift analysis, and sequencing.Diagn Mol Pathol. 1993;2:23-8.
94. Wang W,Kumar P,Whalley J, et al.The mutation status of PAX3 and p53 genes in medulloblastoma.Anticancer Res. 1998;18:849-53.
95. Pazzaglia S,Mancuso M,Tanori M, et al.Modulation of patched-associated susceptibility to radiation induced tumorigenesis by genetic background.Cancer Res. 2004;64:3798-806.
96. Pfaff E,Remke M,Sturm D, et al.TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.J Clin Oncol. 2010;28:5188-96.
97. Northcott PA,Korshunov A,Witt H, et al.Medulloblastoma comprises four distinct molecular variants.J Clin Oncol. 2011;29:1408-14.
98. Tabori U,Baskin B,Shago M, et al.Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations.J Clin Oncol. 2010;28:1345-50.
99. Sadot E,Geiger B,Oren M,Ben-Ze'ev A.Down-regulation of beta-catenin by activated p53.Mol Cell Biol. 2001;21:6768-81.
100. Levina E,Oren M,Ben-Ze'ev A.Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics.Oncogene. 2004;23:4444-53.
101. Damalas A,Ben-Ze'ev A,Simcha I, et al.Excess beta-catenin promotes accumulation of transcriptionally active p53.EMBO J. 1999;18:3054-63.
102. Hogarty MD.The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.Cancer Lett. 2003;197:173-9.
103. Slack AD,Chen Z,Ludwig AD,Hicks J,Shohet JM.MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.Cancer Res. 2007;67:2448-55.
104. Goodrich LV,Milenkovic L,Higgins KM,Scott MP.Altered neural cell fates and medulloblastoma in mouse patched mutants.Science. 1997;277:1109-13.
105. Ashcroft M,Ludwig RL,Woods DB, et al.Phosphorylation of HDM2 by Akt.Oncogene. 2002;21:1955-62.
106. Mayo LD,Donner DB.A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.Proc Natl Acad Sci U S A. 2001;98:11598-603.
107. Ogawara Y,Kishishita S,Obata T, et al.Akt enhances Mdm2-mediated ubiquitination and degradation of p53.J Biol Chem. 2002;277:21843-50.
108. Abe Y,Oda-Sato E,Tobiume K, et al.Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2.Proc Natl Acad Sci U S A. 2008;105:4838-43.
109. Prykhozhij SV.In the absence of Sonic hedgehog, p53 induces apoptosis and inhibits retinal cell proliferation, cell cycle exit and differentiation in zebrafish.PLoS ONE. 2010;5:e13549.
110. Giordana MT,Duo D,Gasverde S, et al.MDM2 overexpression is associated with short survival in adults with medulloblastoma.Neuro Oncol. 2002;4:115-22.
111. Castellino RC,De Bortoli M,Lu X, et al.Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D.J Neurooncol. 2008;86:245-56.
112. Lu X,Ma O,Nguyen TA,Jones SN,Oren M,Donehower LA.The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.Cancer Cell. 2007;12:342-54.
113. Kasuga C,Nakahara Y,Ueda S, et al.Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy: laboratory investigation.J Neurosurg Pediatr. 2008;1:305-13.
114. Marcar L,Maclaine NJ,Hupp TR,Meek DW.Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin.Cancer Res. 2010;70:10362-70.
115. Ferretti E,De Smaele E,Po A, et al.MicroRNA profiling in human medulloblastoma.Int J Cancer. 2009;124:568-77.
116. Grahovac G,Tomac D,Lambasa S,Zoric A,Habek M.Cerebellar glioblastomas: pathophysiology, clinical presentation and management.Acta Neurochir (Wien). 2009;151:653-7.
117. Ohgaki H,Kleihues P.Genetic alterations and signaling pathways in the evolution of gliomas.Cancer Sci. 2009;100:2235-41.
118. Ohgaki H,Kleihues P.Genetic pathways to primary and secondary glioblastoma.Am J Pathol. 2007;170:1445-53.
119. Ohgaki H,Dessen P,Jourde B, et al.Genetic pathways to glioblastoma: a population-based study.Cancer Res. 2004;64:6892-9.
120. Zheng H,Ying H,Yan H, et al.p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.Nature. 2008;455:1129-33.
121. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.Nature. 2008;455:1061-8.
122. Okamoto Y,Di Patre PL,Burkhard C, et al.Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.Acta Neuropathol. 2004;108:49-56.
123. Reilly KM,Loisel DA,Bronson RT,McLaughlin ME,Jacks T.Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.Nat Genet. 2000;26:109-13.
124. Zhu Y,Guignard F,Zhao D, et al.Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.Cancer Cell. 2005;8:119-30.
125. Wade M,Wang YV,Wahl GM.The p53 orchestra: Mdm2 and Mdmx set the tone.Trends Cell Biol. 2010;20:299-309.
126. Tao W,Levine AJ.P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.Proc Natl Acad Sci U S A. 1999;96:6937-41.
127. Tao W,Levine AJ.Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.Proc Natl Acad Sci U S A. 1999;96:3077-80.
128. Weber JD,Taylor LJ,Roussel MF,Sherr CJ,Bar-Sagi D.Nucleolar Arf sequesters Mdm2 and activates p53.Nat Cell Biol. 1999;1:20-6.
129. Reifenberger G,Liu L,Ichimura K,Schmidt EE,Collins VP.Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.Cancer Res. 1993;53:2736-9.
130. Riemenschneider MJ,Buschges R,Wolter M, et al.Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.Cancer Res. 1999;59:6091-6.
131. Nakamura M,Watanabe T,Klangby U, et al.p14ARF deletion and methylation in genetic pathways to glioblastomas.Brain Pathol. 2001;11:159-68.
132. Stegh AH,Brennan C,Mahoney JA, et al.Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor.Genes Dev. 2010;24:2194-204.
133. Stegh AH,Kim H,Bachoo RM, et al.Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma.Genes Dev. 2007;21:98-111.
134. Squatrito M,Brennan CW,Helmy K,Huse JT,Petrini JH,Holland EC.Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas.Cancer Cell. 2010;18:619-29.
135. Bagchi A,Papazoglu C,Wu Y, et al.CHD5 is a tumor suppressor at human 1p36.Cell. 2007;128:459-75.
136. Verhaak RG,Hoadley KA,Purdom E, et al.Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.Cancer Cell. 2010;17:98-110.
137. Stupp R,Hegi ME,van den Bent MJ, et al.Changing paradigms: an update on the multidisciplinary management of malignant glioma.Oncologist. 2006;11:165-80.
138. Bao S,Wu Q,McLendon RE, et al.Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.Nature. 2006;444:756-60.
139. Lowe SW,Ruley HE,Jacks T,Housman DE.p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.Cell. 1993;74:957-67.
140. Lane DP,Fischer PM.Turning the key on p53.Nature. 2004;427:789-90.
141. Brown CJ,Cheok CF,Verma CS,Lane DP.Reactivation of p53: from peptides to small molecules.Trends Pharmacol Sci. 2011;32:53-62.
142. Foster BA,Coffey HA,Morin MJ,Rastinejad F.Pharmacological rescue of mutant p53 conformation and function.Science. 1999;286:2507-10.
143. Bykov VJ,Issaeva N,Shilov A, et al.Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.Nat Med. 2002;8:282-8.
144. Vassilev LT,Vu BT,Graves B, et al.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science. 2004;303:844-8.
145. Chen L,Agrawal S,Zhou W,Zhang R,Chen J.Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.Proc Natl Acad Sci U S A. 1998;95:195-200.
146. Issaeva N,Bozko P,Enge M, et al.Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.Nat Med. 2004;10:1321-8.
147. Vousden KH,Lane DP.p53 in health and disease.Nat Rev Mol Cell Biol. 2007;8:275-83.
148. Jacobs WB,Kaplan DR,Miller FD.The p53 family in nervous system development and disease.J Neurochem. 2006;97:1571-84.
149. Norimura T,Nomoto S,Katsuki M,Gondo Y,Kondo S.p53-dependent apoptosis suppresses radiation-induced teratogenesis.Nat Med. 1996;2:577-80.
150. Nicol CJ,Harrison ML,Laposa RR,Gimelshtein IL,Wells PG.A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice.Nat Genet. 1995;10:181-7.
151. Jones NC,Lynn ML,Gaudenz K, et al.Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function.Nat Med. 2008;14:125-33.
152. Chalepakis G,Goulding M,Read A,Strachan T,Gruss P.Molecular basis of splotch and Waardenburg Pax-3 mutations.Proc Natl Acad Sci U S A. 1994;91:3685-9.
153. Pani L,Horal M,Loeken MR.Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3-dependent development and tumorigenesis.Genes Dev. 2002;16:676-80.
154. Epstein DJ,Vogan KJ,Trasler DG,Gros P.A mutation within intron 3 of the Pax-3 gene produces aberrantly spliced mRNA transcripts in the splotch (Sp) mouse mutant.Proc Natl Acad Sci U S A. 1993;90:532-6.
155. Auerbach R.Analysis of the developmental effects of a lethal mutation in the house mouse.J Exp Zool. 1954;127:305-29.
156. Danilova N,Kumagai A,Lin J.p53 upregulation is a frequent response to deficiency of cell-essential genes.PLoS ONE. 2010;5:e15938.
157. Yang X,Klein R,Tian X,Cheng HT,Kopan R,Shen J.Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway.Dev Biol. 2004;269:81-94.
158. Whelan JT,Forbes SL,Bertrand FE.CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression.Cell Cycle. 2007;6:80-4.
159. Wang C,Qi R,Li N, et al.Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.J Biol Chem. 2009;284:16183-90.
160. He SJ,Stevens G,Braithwaite AW,Eccles MR.Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity.Mol Cancer Ther. 2005;4:996-1003.
161. Underwood TJ,Amin J,Lillycrop KA,Blaydes JP.Dissection of the functional interaction between p53 and the embryonic proto-oncoprotein PAX3.FEBS Lett. 2007;581:5831-5.
162. Langley E,Pearson M,Faretta M, et al.Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.EMBO J. 2002;21:2383-96.
163. Cheng HL,Mostoslavsky R,Saito S, et al.Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice.Proc Natl Acad Sci U S A. 2003;100:10794-9.
164. Harris MJ,Juriloff DM.An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure.Birth Defects Res A Clin Mol Teratol. 2010;88:653-69.